NCT01852578 - Cabazitaxel in Relapsed and Metastatic NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

NSCLC

Interventions

DRUG

Cabazitaxel

Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks

Trial Locations (5)

"Ag. Georgios General Hospital of Chania", Chania

University Hospital of Crete, Dep of Medical Oncology Heraklion, Greece, Heraklion

"IASO General Hospital of Athens Athens, Greece", Athens

Air Forces Military Hospital of Athens Athens, Greece, Athens

"PAPAGEORGIOY General Hospital of Thessaloniki", Thessaloniki